drugset / Trial / NCT01339884

A Study of Resveratrol as Treatment for Friedreich Ataxia

NCT01339884

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effect of two doses of resveratrol taken for a 12 week period, on frataxin levels in individuals with Friedreich ataxia. This study will also measure the effect of resveratrol on markers of oxidative stress, clinical measures of ataxia, and cardiac parameters.

Timeline

Start
2011-04
Primary completion
2012-08
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Resveratrol Small molecule 500 mg
Comparator Resveratrol Small molecule 2.5 g

Indications